TRVN - トレベナ （Trevena Inc.）

Trevena, Inc. (NASDAQ:NASDAQ:TRVN) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ETCompany ParticipantsBarry Shin - Chief Financial OfficerCarrie Bourdow - President and Chief…

Trevena Inc (NASDAQ: TRVN ) announced initial topline OLINVYK data from two related real-world outcomes studies: VOLITION and ARTEMIS. The VOLITION study (n=203 patients) assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting. Initial GI and cognition data are available, with respiratory outcome data expected in mid-2023. OLINVYK-treated patients had a 52.2% GI … Full story available on Benzinga.com

Trevena (TRVN) reported data from two real-world outcomes studies evaluating opioid pain drug Olinvyk (oliceridine). Read more here.

Companies Reporting Before The Bell • Creative Realities (NASDAQ: CREX ) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. • EVgo (NASDAQ: EVGO ) is likely to report quarterly loss at $0.16 per share on revenue of $21.82 million. • Edap TMS (NASDAQ: EDAP ) is likely to report quarterly loss at $0.01 per share on revenue of $17.04 million. • Marketwise (NASDAQ: MKTW ) is estimated to report quarterly earnings at $0.02 per share on revenue of $114.83 million. • Manchester United (NYSE: MANU ) is projected to report quarterly loss at $0.01 per share on revenue of $172.27 million. • Neogen (NASDAQ: NEOG ) is projected to report quarterly loss at $0.01 per share on revenue of $218.86 million. • Cazoo Gr (NYSE: CZOO ) is likely to report earnings for its fourth quarter. • Avadel Pharmaceuticals (NASDAQ: AVDL ) is likely to report earnings for its fourth quarter. • Altisource Portfolio (NASDAQ: ASPS ) is projected to report quarterly loss at $0.65 per share on revenue of $33.

CHESTERBROOK, Pa. (AP) — CHESTERBROOK, Pa. (AP) — Trevena Inc. (TRVN) on Thursday reported a loss of $7 million in…

Trevena, Inc. (NASDAQ:NASDAQ:TRVN) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ETCompany ParticipantsBarry Shin - Chief Financial OfficerCarrie Bourdow - President and Chief…

Trevena Inc (NASDAQ: TRVN ) announced initial topline OLINVYK data from two related real-world outcomes studies: VOLITION and ARTEMIS. The VOLITION study (n=203 patients) assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting. Initial GI and cognition data are available, with respiratory outcome data expected in mid-2023. OLINVYK-treated patients had a 52.2% GI … Full story available on Benzinga.com

Trevena (TRVN) reported data from two real-world outcomes studies evaluating opioid pain drug Olinvyk (oliceridine). Read more here.

Companies Reporting Before The Bell • Creative Realities (NASDAQ: CREX ) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. • EVgo (NASDAQ: EVGO ) is likely to report quarterly loss at $0.16 per share on revenue of $21.82 million. • Edap TMS (NASDAQ: EDAP ) is likely to report quarterly loss at $0.01 per share on revenue of $17.04 million. • Marketwise (NASDAQ: MKTW ) is estimated to report quarterly earnings at $0.02 per share on revenue of $114.83 million. • Manchester United (NYSE: MANU ) is projected to report quarterly loss at $0.01 per share on revenue of $172.27 million. • Neogen (NASDAQ: NEOG ) is projected to report quarterly loss at $0.01 per share on revenue of $218.86 million. • Cazoo Gr (NYSE: CZOO ) is likely to report earnings for its fourth quarter. • Avadel Pharmaceuticals (NASDAQ: AVDL ) is likely to report earnings for its fourth quarter. • Altisource Portfolio (NASDAQ: ASPS ) is projected to report quarterly loss at $0.65 per share on revenue of $33.

CHESTERBROOK, Pa. (AP) — CHESTERBROOK, Pa. (AP) — Trevena Inc. (TRVN) on Thursday reported a loss of $7 million in…

Trevena (TRVN) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open.The consensus EPS Estimate is -$0.10 (-11.1% Y/Y) and the consensus Revenue…

Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET

Trevena Inc. (NASDAQ:TRVN) marked $0.22 per share on Monday, down from a previous closing price of $0.25. While Trevena Inc. has underperformed by -10.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TRVN fell by -83.37%, with highs and lows ranging from $1.54 to $0.18, whereas […]

The trading price of Trevena Inc. (NASDAQ:TRVN) closed lower on Friday, July 29, closing at $0.25, -5.67% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $0.2366 and $0.254. In examining the 52-week price action we see that the stock hit a 52-week high … Should This Make Trevena Inc. (NASDAQ: TRVN) Investors Worry? Read More »

CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor for the purchase and sale of 1,800 shares of Series A convertible preferred stock (“Series A Preferred”) and 200 shares of Series B convertible preferred stock (“Series B Preferred”) and warrants exercisable to purchase up to an aggregate of 8,000,000 shares of common stock. Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 8,000,000 shares of common stock. The warrants have an exercise price of $0.263 per share, will be exercisable beginning on the later of six months following the date of issuance and the effective date of a reverse stock split of the Company’s common stock in an amount sufficient to permit the exercise in full of the warrants, subject to stockholder approval of the reverse stock split, and will expire five and one-half years following the date of issuance.